Skip to main content
SRTA
NASDAQ Industrial Applications And Services

Strata Critical Medical Reports Strong Q1 2026 Results, Swings to Profit, and Secures New $30M ABL Facility

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
8
Price
$5.325
Mkt Cap
$467.969M
52W Low
$2.725
52W High
$6.02
Market data snapshot near publication time

summarizeSummary

Strata Critical Medical, Inc. reported robust Q1 2026 financial results, including an 87.4% year-over-year revenue increase and a swing to net income, alongside securing a new $30 million asset-based revolving credit facility to enhance liquidity.


check_boxKey Events

  • Strong Q1 2026 Financial Performance

    Revenue increased 87.4% year-over-year to $67.4 million, with gross profit up 100.2% to $14.1 million. The company swung from a net loss of $3.5 million in Q1 2025 to a net income of $2.2 million in Q1 2026. Adjusted EBITDA from continuing operations surged to $6.4 million from $0.4 million.

  • Enhanced Liquidity with New ABL Facility

    The company established a secured asset-based revolving credit facility of up to $30.0 million, with an option to increase by an additional $20.0 million, providing significant financial flexibility. No amounts were outstanding as of March 31, 2026.

  • Increased Cash Position

    Cash and cash equivalents rose significantly to $58.7 million as of March 31, 2026, from $31.0 million at year-end 2025.

  • Strategic Acquisition Completed

    Subsequent to the quarter, Keystone (a subsidiary) acquired Ohio Valley Perfusion Associates for $1.0 million cash, further expanding the Clinical segment.


auto_awesomeAnalysis

This 10-Q confirms and elaborates on the strong first-quarter performance, showcasing a significant financial turnaround with substantial revenue growth and a swing to profitability. The establishment of a new ABL facility provides a considerable boost to liquidity and financial flexibility, which is crucial for a growth-oriented company. The successful integration of the Keystone acquisition is evident in the strong Clinical segment revenue and improved gross margins. The reduction in warrant liabilities is also a positive, albeit non-cash, development. Investors should view this report as a strong indicator of the company's successful strategic shift and improved financial health.

At the time of this filing, SRTA was trading at $5.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $468M. The 52-week trading range was $2.73 to $6.02. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SRTA - Latest Insights

SRTA
May 06, 2026, 11:53 AM EDT
Filing Type: 10-Q
Importance Score:
8
SRTA
May 06, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
7
SRTA
Apr 30, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
SRTA
Apr 16, 2026, 5:31 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
SRTA
Apr 14, 2026, 8:54 AM EDT
Filing Type: DEF 14A
Importance Score:
8
SRTA
Apr 08, 2026, 5:03 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
SRTA
Apr 07, 2026, 5:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
SRTA
Mar 03, 2026, 11:52 AM EST
Filing Type: 10-K
Importance Score:
8
SRTA
Mar 03, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
SRTA
Feb 05, 2026, 9:09 AM EST
Filing Type: 8-K
Importance Score:
8